|Articles|May 1, 2003
No Differences
San Francisco - Alefacept (Amevive) offers efficacy for a broad spectrum of patients with chronic plaque psoriasis who are considered candidates for systemic therapy or phototherapy, according to the results of a retrospective study.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
The SkinCARE Questionnaire: Assessing the Psychological Dimensions of Skin Health Beyond Disease
5














